Soporte_Pediatrico_para_el_paciente_Oncologico_Febrero_2013

Capítulo 6
Tratamiento quirúrgico
Se estima que, aproximadamente, un tercio de las extravasaciones de agentes vesicantes evoluciona a
la ulceración. 5,10 No hay un consenso general para la indicación de tratamiento quirúrgico. Se sugiere el
tratamiento conservador de las lesiones, por lo que el uso del debridamiento quirúrgico del tejido necrótico
queda relegado a los casos que muestran úlceras crónicas sin tendencia a la epitelización y/o dolor persistente
intratable. 4,5,10,12,20,22
REFERENCIAS BIBLIOGRÁFICAS
1
Mader I, Furst-Weger P, Mader RM, Semenitz E, Wassertheurer S.
Extravasation of cytotoxic agents. Compendium for prevention and
management. 2nd edition Austria: Springer;2009.
2
Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto S, Koga
T, et al. Protection against the extravasation of anticancer drugs by
standardization of management system. Hosp Pharm. 2008;43:571-76.
3
Langer SW. Extravasation of chemotherapy. Curr Oncol Rep
2010;12: 242-46.
4
Schrijvers DL. Extravasation: a dreaded complication of
chemotherapy. Ann Oncol. 1988 Nov; 6(11):1732-5.
5
Ener RA, Meglathery SB, Styler M. Extravasation of systemic
hemato-oncological therapies. Ann Oncol. 2004 ;15(6):858-62.
6
Schulmeister L. Extravasation management: Clinical Update. Semin
Oncol Nurs. 2011; 27(1):82-90
7
Wengstrom Y, Margulies A. European Oncology Nursing Society
extravasation guidelines. Eur J Oncol Nurs. 2008;12 (4):357-61.
8
Goolsby T V, Lombardo F A. Extravasation of chemotherapeutic
agents: prevention and treatment. Semin Oncol. 2006; 33(1):139-4.
9
Hadaway L. Infiltration and Extravasation. Am J Nurs. 2007;
107(8):64-72.
10
Alfaro-Rubio A, SanMartin O, Requena C, Llombart B, Botella-
Estrada R, Nagore E, et al. Extravasación de agentes citostáticos: una
complicación grave del tratamiento oncológico. Actas Dermosifiliogr.
2006;97(3):169-76.
11
Conde-Estévez D, Mateu-de Antonio J. Actualización del manejo
de extravasaciones de agentes citostáticos. Farm Hosp. 2012;
36(1):34-42.
12
Perez Fidalgo MD, García Fabregat RN, Cervantes MD, Margulies
RN, Vidall RN, Roila MD on behalf of the ESMO Guidelines Working
Group. Management of chemotherapy extravasation: ESMO-EONS
Clinical Practice Guidelines. Ann Oncol. 2012;23(7):167-73.
13
Dougherty L. Extravasation: prevention, recognition and
management. Nurs Stand 2010 Sept 1-7; 24(52):48-55 quiz 56,60.
14
Mateu J, Massó-Muniesa J, Clopés A, Òdena E, Trullàs M.
Consideraciones en el manejo de la extravasación de citostáticos.
Farm Hosp. 1997;21(4):187-9.
15
Schulmeister L, Camp-Sorrell D. Chemotherapy extravasation from
implanted ports.Oncol Nurs Forum. 2000;27(3):531-8.
16
Fuente Gonzalez MJ et al. Efectos secundarios cutáneos
de los tratamientos sistémicos del cáncer (I): quimioterapia y
hormonoterapia. Piel 2009, 24(07):368-79
17
Kurul S, Saip P, Aydin T. Totally implantable venous-access
ports: local problems and extravasation injury.Lancet Oncol.
2002;3(11):684-9
18
Lauvin R, Miglianico L, Hellegonarch R. Skin cáncer occuring 10
years after the extravasation of doxorrubicin. N Engl J Med. 1995,
332(11):754.
19
Kahler C, Mustroph D, Hauschild A. Current recommendations
for prevention and therapy of extravasation reactions in dermatooncology.
JDDG; 2009,7(1):21-28.
20
Doellman D, Hadaway L, Bowe- Geddes LA, et al. Infiltration and
extravasation: update on prevention and management. J Infus Nurs.
2009; 32(4):203-11
21
Schulmeister L. Managing Vesicant Extravasations. Oncologist.
2008; 13(3):284-8.
22
Langer SW, Sehested M, Jensen PB. Anthracycline extravasation:
a comprehensive review of experimental and clinical treatments.
Tumori. 2009;95:273-82.
23
Kane RC, Mc Guinn Jr, Dagher R, Justice R, Pazdur R. Dexrazoxane
(Totec): FDA Review and approval for the treatment of accidental
extravasation following intravenous anthracycline chemotherapy.
Oncologist 2008; 13(4):445-50.
24
Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, et al.
Treatment of anthracycline extravasation with Savene (dexrazoxane):
results from two prospective clinical multicentre studies. Ann Oncol.
2007; 18(3):546-50.
25
National Extravasation Information System., Position Statement
on dexrazoxane in the Treatment of Anthracycline Extravasation.
[Documento en Internet]. 2007 [Acceso 25 octubre 2012]. Disponible
en http://www.extravasation.org.uk/Dexrazoxane.htm
85